Who is sponsoring NCT04085159?

NCT04085159 is sponsored by Shenzhen Geno-Immune Medical Institute.

What drugs are being tested in NCT04085159?

Interventions in NCT04085159: Antigen-specific T cells CART/CTL and DCvac.

Is NCT04085159 still recruiting?

NCT04085159 is currently status unknown. Last updated 12 June 2020.

Last reviewed 2020-06-12 · How we verify

NCT04085159

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Immunotherapy Based on Antigen-specific Immune Effector Cells Targeting Neurofibromatosis or Schwannomatosis

Status unknown Phase 1, PHASE2 Last updated 12 June 2020

What this trial tests

Phase 1, PHASE2 trial testing Antigen-specific T cells CART/CTL and DCvac in Cancer in 100 participants. Status unknown.

Timeline

1 September 2019

Primary endpoint
31 January 2021

31 December 2022

Quick facts

Lead sponsor	Shenzhen Geno-Immune Medical Institute
Phase	Phase 1, PHASE2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	1 September 2019
Primary completion	31 January 2021
Estimated completion	31 December 2022
Sites	3 locations across China

Drugs / interventions tested

Antigen-specific T cells CART/CTL and DCvac — full drug profile →

Conditions studied

Cancer — all drugs for Cancer →

Sponsor

Shenzhen Geno-Immune Medical Institute

Who can join

Adults 1 to 80, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary objective of this study is to verify the safety of antigen-specific T cells (CAR-T) and engineered immune effector cytotoxic T cells (EIE) modified by immunoregulatory genes and immune modified dendritic cell vaccine (DCvac) in the treatment of neurofibromatosis or schwannoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Current Understanding of Neurofibromatosis Type 1, 2, and Schwannomatosis.
Tamura R. · · 2021 · cited 153× · PMID 34072574 · DOI 10.3390/ijms22115850
Trial watch: Dendritic cell (DC)-based immunotherapy for cancer.
Laureano RS, Sprooten J, Vanmeerbeerk I, Borras DM, et al · · 2022 · cited 101× · PMID 35800158 · DOI 10.1080/2162402x.2022.2096363
CARs: Beyond T Cells and T Cell-Derived Signaling Domains.
Sievers NM, Dörrie J, Schaft N. · · 2020 · cited 27× · PMID 32429316 · DOI 10.3390/ijms21103525
The genetic landscape and possible therapeutics of neurofibromatosis type 2.
Ghalavand MA, Asghari A, Farhadi M, Taghizadeh-Hesary F, et al · · 2023 · cited 25× · PMID 37217995 · DOI 10.1186/s12935-023-02940-8
Trial watch: anticancer vaccination with dendritic cells.
Borges F, Laureano RS, Vanmeerbeek I, Sprooten J, et al · · 2024 · cited 18× · PMID 39398476 · DOI 10.1080/2162402x.2024.2412876
Clinical trials targeting neurofibromatoses-associated tumors: a systematic review.
Roman Souza G, Abdalla A, Mahadevan D. · · 2022 · cited 7× · PMID 35291225 · DOI 10.1093/noajnl/vdac005
Immunotherapy for Pediatric Brain and Spine Tumors: Current State and Future Directions.
Estevez-Ordonez D, Gary SE, Atchley TJ, Maleknia PD, et al · · 2023 · cited 5× · PMID 36549282 · DOI 10.1159/000528792
Quality of life assessment in schwannomatosis - A systematic review.
Lawson McLean AC, Rosahl SK, Lawson McLean A, Fehringer P, et al · · 2025 · cited 2× · PMID 40510571 · DOI 10.1016/j.bas.2025.104279

Verify or expand the search:

Other trials of Antigen-specific T cells CART/CTL and DCvac

Trials testing the same drug.

NCT05262673 — NGS-MRD Assessment of Combination Immunotherapies Targeting B-ALL · Phase 1 · unknown

Other recruiting trials for Cancer

Currently open trials in the same condition.

NCT07390045 — Exercise and Cognitive Rehabilitation Interventions for Older Cancer Survivors · NA · recruiting
NCT07528547 — Hypersight and Ethos In Pediatric Radiotherapy · NA · recruiting
NCT07481890 — Feasibility and Efficacy of the EMDR Toolbox Method in Cancer Patients. · NA · recruiting
NCT07402057 — Implementation and Evaluation of a Program Aimed at Facilitating Palliative Care Conversations · NA · recruiting
NCT07305740 — On-Trac: An Online Intervention for Cancer Survivors Managing Anxiety · NA · recruiting

Other Shenzhen Geno-Immune Medical Institute trials

Trials by the same sponsor.

NCT07501156 — H3K27M-specific Immune Effector Cells Targeting DMG/DIPG · Phase 1, PHASE2 · recruiting
NCT07495956 — cfMSC Therapy for Diabetes · Phase 1, PHASE2 · recruiting
NCT07477600 — cfMSC Stem Cell Therapy Targeting COPD · Phase 1, PHASE2 · recruiting
NCT07180927 — DLL3 CAR-T Therapy Targeting Brain Tumors · Phase 1, PHASE2 · recruiting
NCT07193966 — NG2 and DLL3 CAR-T Cells Targeting Melanoma · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04085159 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shenzhen Geno-Immune Medical Institute
Last refreshed: 12 June 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04085159.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing